These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

616 related items for PubMed ID: 30922594

  • 1. Effects of Hydroxychloroquine on Proteinuria in IgA Nephropathy: A Randomized Controlled Trial.
    Liu LJ, Yang YZ, Shi SF, Bao YF, Yang C, Zhu SN, Sui GL, Chen YQ, Lv JC, Zhang H.
    Am J Kidney Dis; 2019 Jul; 74(1):15-22. PubMed ID: 30922594
    [Abstract] [Full Text] [Related]

  • 2. Comparison of the effects of hydroxychloroquine and corticosteroid treatment on proteinuria in IgA nephropathy: a case-control study.
    Yang YZ, Chen P, Liu LJ, Cai QQ, Shi SF, Chen YQ, Lv JC, Zhang H.
    BMC Nephrol; 2019 Aug 05; 20(1):297. PubMed ID: 31382914
    [Abstract] [Full Text] [Related]

  • 3. Effects of Hydroxychloroquine on Proteinuria in Immunoglobulin A Nephropathy.
    Yang YZ, Liu LJ, Shi SF, Wang JW, Chen YQ, Lv JC, Zhang H.
    Am J Nephrol; 2018 Aug 05; 47(3):145-152. PubMed ID: 29502121
    [Abstract] [Full Text] [Related]

  • 4. The efficacy and safety of hydroxychloroquine versus leflunomide in patients with IgA nephropathy: a single-center experience.
    He WJ, Wang J, Liu N, Li GY, Zhu XW, Yao L, Liu LL.
    J Nephrol; 2024 May 05; 37(4):933-940. PubMed ID: 38225440
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Treatment effects of Chinese medicine (Yi-Qi-Qing-Jie herbal compound) combined with immunosuppression therapies in IgA nephropathy patients with high-risk of end-stage renal disease (TCM-WINE): study protocol for a randomized controlled trial.
    Li S, Li JP.
    Trials; 2020 Jan 06; 21(1):31. PubMed ID: 31907076
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Efficacy and Safety of Hydroxychloroquine in Patients with IgA Nephropathy: A Meta-Analysis.
    Zhang Z, Liu X, Ye P, Xie C, Kong Y.
    Arch Esp Urol; 2024 Jan 06; 77(1):16-24. PubMed ID: 38374008
    [Abstract] [Full Text] [Related]

  • 13. Effect of hydroxychloroquine in patients with IgA nephropathy with insufficient responses to immunosuppressive therapy: a retrospective case-control study.
    Tang C, Lv JC, Shi SF, Chen YQ, Liu LJ, Zhang H.
    BMC Nephrol; 2020 Nov 10; 21(1):469. PubMed ID: 33172397
    [Abstract] [Full Text] [Related]

  • 14. Effects of Hydroxychloroquine on Proteinuria in IgA Nephropathy: A Systematic Review and Meta-Analysis.
    Zhang J, Lu X, Feng J, Li H, Wang S.
    Biomed Res Int; 2021 Nov 10; 2021():9171715. PubMed ID: 34901280
    [Abstract] [Full Text] [Related]

  • 15. Effectiveness of Mycophenolate Mofetil Among Patients With Progressive IgA Nephropathy: A Randomized Clinical Trial.
    Hou FF, Xie D, Wang J, Xu X, Yang X, Ai J, Nie S, Liang M, Wang G, Jia N, MAIN Trial Investigators.
    JAMA Netw Open; 2023 Feb 01; 6(2):e2254054. PubMed ID: 36745456
    [Abstract] [Full Text] [Related]

  • 16. Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial.
    Lafayette R, Kristensen J, Stone A, Floege J, Tesař V, Trimarchi H, Zhang H, Eren N, Paliege A, Reich HN, Rovin BH, Barratt J, NefIgArd trial investigators.
    Lancet; 2023 Sep 09; 402(10405):859-870. PubMed ID: 37591292
    [Abstract] [Full Text] [Related]

  • 17. Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial.
    Rovin BH, Barratt J, Heerspink HJL, Alpers CE, Bieler S, Chae DW, Diva UA, Floege J, Gesualdo L, Inrig JK, Kohan DE, Komers R, Kooienga LA, Lafayette R, Maes B, Małecki R, Mercer A, Noronha IL, Oh SW, Peh CA, Praga M, Preciado P, Radhakrishnan J, Rheault MN, Rote WE, Tang SCW, Tesar V, Trachtman H, Trimarchi H, Tumlin JA, Wong MG, Perkovic V, DUPRO steering committee and PROTECT Investigators.
    Lancet; 2023 Dec 02; 402(10417):2077-2090. PubMed ID: 37931634
    [Abstract] [Full Text] [Related]

  • 18. The efficacy and safety of hydroxychloroquine in pregnant patients with IgA nephropathy: A retrospective cohort study.
    Tang C, Si FL, Yao YX, Lv JC, Shi SF, Chen YQ, Liu LJ, Zhang H.
    Nephrology (Carlton); 2022 Feb 02; 27(2):155-161. PubMed ID: 34713949
    [Abstract] [Full Text] [Related]

  • 19. Oral calcitriol for reduction of proteinuria in patients with IgA nephropathy: a randomized controlled trial.
    Liu LJ, Lv JC, Shi SF, Chen YQ, Zhang H, Wang HY.
    Am J Kidney Dis; 2012 Jan 02; 59(1):67-74. PubMed ID: 22019331
    [Abstract] [Full Text] [Related]

  • 20. Effect of Oral Methylprednisolone on Decline in Kidney Function or Kidney Failure in Patients With IgA Nephropathy: The TESTING Randomized Clinical Trial.
    Lv J, Wong MG, Hladunewich MA, Jha V, Hooi LS, Monaghan H, Zhao M, Barbour S, Jardine MJ, Reich HN, Cattran D, Glassock R, Levin A, Wheeler DC, Woodward M, Billot L, Stepien S, Rogers K, Chan TM, Liu ZH, Johnson DW, Cass A, Feehally J, Floege J, Remuzzi G, Wu Y, Agarwal R, Zhang H, Perkovic V, TESTING Study Group.
    JAMA; 2022 May 17; 327(19):1888-1898. PubMed ID: 35579642
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 31.